Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: August 23, 2011
Context: The filing discloses a share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 800,000 Ordinary shares (25 pence each).
- Price Range: Highest price paid was 1,305 pence per share; lowest price paid was 1,273 pence per share.
- Treasury Shares Held: 502,996,816 shares (representing 9.00% of total issued share capital and 9.89% of total voting rights).
- Shares in Issue: 5,084,073,880 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 800,000 repurchased shares. This transaction increased the proportion of Treasury shares held by the Company to 9.00% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 800,000 share repurchase based on the disclosed price range (1,273–1,305 pence).
- Confirm the updated total issued share capital and voting rights structure post-cancellation.
- Review the remaining authorization for share buybacks under the May 5, 2011 shareholder mandate.
- Check subsequent filings for further repurchase activity or changes in Treasury share holdings.